Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Expert Opin Ther Pat. 2010 Apr;20(4):459-69. doi: 10.1517/13543771003674409.
Importance of field: IL-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase of the Tec family. It plays an important role in T cell signaling and the production of various pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10 and IL-13. Inhibition of Itk has been a target for the treatment of diseases related to inflammation disorders such as psoriasis and allergic asthma. Rich resources on the structural information for Itk made discovery of novel selective Itk inhibitors blossom in the past decade.
In this report, distinct structural classes of specific Itk inhibitors are summarized and their in vitro/in vivo properties are discussed.
A summary of 21 patents including 16 different chemical structure classes of Itk inhibitors. The in vivo efficacies of some of the inhibitors in animal models are also discussed.
Although some of the inhibitors show efficacy in different animal models, which implies potential for therapeutic use in human, there is not yet a chemical entity reported in clinical trials. The prospects for Itk inhibitors will rely on the quality of the compound and the validity of the target in patients within the selected therapeutic area.
白细胞介素 2 可诱导 T 细胞激酶(Itk)是 Tec 家族的一种非受体酪氨酸激酶。它在 T 细胞信号转导和各种促炎细胞因子的产生中发挥重要作用,如白细胞介素 2、白细胞介素 4、白细胞介素 5、白细胞介素 10 和白细胞介素 13。抑制 Itk 一直是治疗与炎症紊乱相关疾病(如银屑病和过敏性哮喘)的目标。过去十年中,由于 Itk 的结构信息资源丰富,新型选择性 Itk 抑制剂的发现如雨后春笋般涌现。
在本报告中,总结了不同结构类别的特异性 Itk 抑制剂,并讨论了它们的体外/体内特性。
包括 16 种不同化学结构类别的 Itk 抑制剂在内的 21 项专利的摘要。还讨论了一些抑制剂在动物模型中的体内疗效。
尽管一些抑制剂在不同的动物模型中显示出疗效,这意味着在人类中具有治疗应用的潜力,但尚未有化学实体在临床试验中报告。Itk 抑制剂的前景将取决于所选治疗领域中化合物的质量和目标的有效性。